Medpace Holdings, Inc. $MEDP Shares Bought by Abacus FCF Advisors LLC

Abacus FCF Advisors LLC lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,663 shares of the company’s stock after buying an additional 3,917 shares during the quarter. Abacus FCF Advisors LLC owned approximately 0.07% of Medpace worth $10,624,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in MEDP. Wasatch Advisors LP raised its position in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the period. Mawer Investment Management Ltd. increased its stake in shares of Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares in the last quarter. AQR Capital Management LLC lifted its stake in Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock valued at $193,269,000 after buying an additional 81,637 shares in the last quarter. TD Asset Management Inc lifted its stake in Medpace by 15.6% in the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after buying an additional 61,764 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its holdings in Medpace by 11.4% in the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after buying an additional 45,435 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares in the company, valued at $470,787,603.56. This trade represents a 7.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 387,925 shares of company stock valued at $233,386,647 over the last 90 days. 20.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and increased their target price for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Mizuho increased their price objective on Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Truist Financial set a $555.00 target price on shares of Medpace in a research report on Monday, October 27th. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $490.82.

Medpace Stock Performance

MEDP opened at $569.98 on Tuesday. The stock has a market capitalization of $16.06 billion, a PE ratio of 39.86, a P/E/G ratio of 2.14 and a beta of 1.43. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $626.26. The business’s 50 day moving average price is $580.13 and its 200 day moving average price is $484.52.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.